TY - JOUR
T1 - Changes in post-treatment cardiac PET avidity predict overall survival in lung cancer patients treated with chemoradiation
T2 - Secondary analysis of the ACRIN 6668/RTOG 0235 clinical trial
AU - Miller, Ryan
AU - Santangelo, Tess
AU - Forghani-Arani, Farnoush
AU - Rusthoven, Chad
AU - Chen, Yingxuan
AU - Castillo, Edward
AU - Castillo, Richard
AU - Guerrero, Thomas
AU - Vinogradskiy, Yevgeniy
N1 - Publisher Copyright:
© 2022 The Author(s)
PY - 2022/6
Y1 - 2022/6
N2 - The purpose of this work was to use data from a large co-operative group trial to evaluate whether metabolic FDG-PET changes in the heart for lung cancer patients can predict for clinical outcomes. The study found that cardiac SUV changes following definitive chemoradiation are significantly (HR 0.811, 95% CI 0.68–0.96, p = 0.017) associated with overall survival in locally advanced NSCLC patients. If validated in a prospective cohort, our data show the potential for cardiac metabolic changes to be an early predictor for clinical outcomes.
AB - The purpose of this work was to use data from a large co-operative group trial to evaluate whether metabolic FDG-PET changes in the heart for lung cancer patients can predict for clinical outcomes. The study found that cardiac SUV changes following definitive chemoradiation are significantly (HR 0.811, 95% CI 0.68–0.96, p = 0.017) associated with overall survival in locally advanced NSCLC patients. If validated in a prospective cohort, our data show the potential for cardiac metabolic changes to be an early predictor for clinical outcomes.
KW - Cardiac toxicity
KW - Functional imaging
KW - Lung cancer
UR - http://www.scopus.com/inward/record.url?scp=85128299663&partnerID=8YFLogxK
U2 - 10.1016/j.radonc.2022.04.003
DO - 10.1016/j.radonc.2022.04.003
M3 - Article
C2 - 35413391
AN - SCOPUS:85128299663
SN - 0167-8140
VL - 171
SP - 22
EP - 24
JO - Radiotherapy and Oncology
JF - Radiotherapy and Oncology
ER -